ClinicalTrials.gg
RecruitingNCT07633470RESOLVEUpdated Oct 19, 2026

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

A Phase 4 interventional study of Zunveyl® in Alzheimer Disease, sponsored by Alpha Cognition, Inc. Recruiting at 22 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Alpha Cognition, Inc · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 19, 20268 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
529th of 1,609
150 · median 73
Started
2026
with 90 others
Phase 4
60 of 1,940
7 open now
Primary completion
2027-04
later than 163 of 444 live
Registered
1,894th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 529th largest by planned enrollment of the 1,609 interventional ones that give a count, is one of 91 that started in 2026, is one of 60 in phase 4, reaches primary completion later than 163 of the 444 other live ones, and was the 1,894th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Acetylcholinesterase inhibitor
  • Galantamine
  • Delayed-release tablets
  • Cognitive impairment
  • benzgalantamine
  • Zunveyl
  • nicotinic acetylcholine receptor agonist
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female outpatients aged 50 years and greater at the time of .
  2. Diagnosis of probable Alzheimer's disease in accordance with the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, supported by biomarker confirmation using the Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test.
  3. Cognitive impairment consistent with mild-to-moderate Alzheimer's disease, confirmed at Screening by the Saint Louis University Mental Status (SLUMS) examination, with scores meeting the following criteria based on education level:

    1. Less than high school education: SLUMS score 10 -18
    2. High school education or higher: SLUMS score 10 - 20
  4. The participant must be capable of providing informed consent; if not, a legally authorized representative (LAR)/caregiver may provide consent in compliance with federal and Institutional Review Board (IRB) regulations.
  5. Participant currently receiving non-exclusionary chronic medications are eligible, provided doses have been stable for greater than or equal to [>=] 4 weeks.
  6. Any recent medication changes at baseline (less than 8 weeks) should be reviewed to confirm they are not expected to confound efficacy or safety assessments.
  7. Availability of a reliable full-time caregiver or study partner who serves as a knowledgeable informant and:

    1. Has at least 20 hours per week of direct contact with the participant;
    2. Is capable of consistently completing tolerability assessments and the Neuropsychiatric Inventory (NPI) across study visits;
    3. Can observe and accurately report tolerability, neuropsychiatric symptoms (including sleep), and caregiver distress;
    4. Is available and willing to participate in all required study visits and assessments.
  8. Participants must not have received disallowed concomitant medications within 2 weeks or 5 half-lives (whichever is longer) prior to baseline.
  9. Compliance with washouts will be confirmed by medication history review.
  10. The participant and caregiver must be willing and able to comply with all study procedures, including visits, assessments, and follow-up in an outpatient setting.

Exclusion criteria

Exclusion Criteria:

  1. Dementia due to causes other than Alzheimer's disease, including but not limited to vascular dementia, frontotemporal dementia, or substance/medication-induced dementia, Parkinson's disease dementia and Lewy body dementia, Huntington's dementia, or any other types.
  2. Negative biomarkers result on the Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, indicating lack of biomarker support for a diagnosis of probable Alzheimer's disease according to the 2024 NIA-AA criteria.
  3. Hospitalization in a psychiatric or mental health facility (For example [e.g.], psychiatric hospital, inpatient ward) at screening or within 3 months prior to screening.
  4. Any concurrent or unstable medical condition that, in the investigator's judgment, could interfere with study conduct, confound interpretation of study data, or pose an undue risk to the participant's safety. Includes but is not limited to:

    1. within the past 2 years, except for adequately treated non-melanotic skin cancer, localized prostate cancer or cervical cancer in situ (other non- malignancies may be allowed with medical monitor approval).
    2. Hematologic, endocrine, metabolic, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disorders that are unstable or progressive.
    3. Cardiovascular examples: three documented episodes of blood pressure greater than (>)185/100 millimeters of mercury (mmHg), unstable ischemic heart disease, dilated cardiomyopathy, unstable valvular disease, cardiac conduction abnormalities, or bradycardia (participants will be excluded if resting (awake) heart rate (HR) less than (\<) 50 beats per minute (bpm) confirmed on repeat, or any symptomatic bradycardia.
  5. Current active clinical diagnosis of delirium, psychosis or psychotic disorder, per , 5th Edition (DSM-5) criteria.
  6. Active major depression requiring initiation or recent change of antidepressant therapy within 2 months prior to Screening.
  7. Active symptoms of diarrhea, nausea, vomiting, or abdominal pain/discomfort or any Gastrointestinal (GI) condition that may impact IP absorption, e.g. gastric bypass surgery during screening or scheduled or prn medications to treat these conditions (e.g., loperamide, ondansetron, antispasmodic drugs).
  8. History of seizure disorder, anorexia nervosa, or bulimia.
  9. Acute delirium at baseline (e.g., positive Confusion Assessment Method [CAM]) that has not been resolved prior to enrollment.
  10. Known or to Zunveyl® or galantamine-containing products.
  11. Use of an drug or device for neuropsychiatric symptoms within 30 days or 5 half-lives, whichever is longer prior to Baseline.
  12. \<12 months, or a hospice/palliative plan of care inconsistent with study participation.
  13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, may place the participant at risk, interfere with assessments, or compromise study participation.
  14. Any participant currently receiving or who has ever received Zunveyl®.
  15. Weight loss of >10 in the 6-month period prior to screening.
  16. Any planned general surgery during the duration of the study.
  17. History of Stevens-Johnson Syndrome (TENS).
  18. Significantly abnormal labs including Estimated (eGFR) \<10 or Liver function Tests (LFTs) >2* (ULN).
  19. Concomitant medications that cannot be stopped including strong Cytochrome P450 (CYP) inhibitors/inducers of 3A4 or 2D6 or a high anticholinergic burden defined as an Anticholinergic Cognitive Burden (ACB) score > 3 within 28 days prior to baseline. Any new neuropsychiatric medication that would need to be initiated during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Zunveyl®

    Participants will receive Zunveyl® at a dose of 5 milligrams (mg), delayed release tablets, orally, twice daily (BID) from Weeks 1 to 4, followed by 10 mg, delayed release tablets, orally, BID for the subsequent Weeks 5 to12.

    Drug: Zunveyl®

Interventions

  • DrugZunveyl®

    Zunveyl® delayed release oral tablets.

    Also known as: Benzgalantamine

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Week 1 up to Week 12

  2. Percentage of Participants who Discontinued due to AEs

    Time frame: From Week 1 up to Week 12

  3. Number of Participants with Treatment Interruptions or Dose Reductions

    Time frame: From Week 1 up to Week 12

  4. Global Tolerability Score

    Functional Assessment of Chronic Illness Therapy (FACIT) General Physical Well-Being domain Item 5 (GP5) will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Higher scores indicate greater bother from treatment side effects and worse treatment toxicity.

    Time frame: At Weeks 1, 2, 4, 6, 8 12, and 17

Secondary outcomes

  1. Change from Baseline in Neuropsychiatric Symptoms as Measured by Neuropsychiatric Inventory - 12 Domain (NPI-12) Total Score up to Week 12

    The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions. NPI: Total score ranges from 0 to 144, with higher scores indicating worse neuropsychiatric symptoms. Each domain is scored as frequency × severity (0-12 per domain). Assesses 12 domains including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and night-time behavior disorders, and appetite/eating abnormalities.

    Time frame: Baseline up to Week 12

  2. Change from Baseline in Total Caregiver Distress Score up to Week 12

    The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions. NPI: Total score ranges from 0 to 144, with higher scores indicating worse neuropsychiatric symptoms. Each domain is scored as frequency × severity (0-12 per domain). Assesses 12 domains including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and night-time behavior disorders, and appetite/eating abnormalities.

    Time frame: Baseline up to Week 12

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 8, 2026
StartActual
May 20, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 United States)
  • Progeny Psychiatric Clinic - Irvine · Irvine, United States
  • Accel Research - NeuroStudies · Decatur, United States
  • Josephson Wallack Munshower Neurology P.C. · Indianapolis, United States
  • ActivMed Practices & Research, LLC · Methuen, United States
  • Adams Clinical - Watertown · Watertown, United States
  • Mt. Olympus Medical Research, Llc - Katy · Katy, United States
  • Flourish Research Andersonville · Northbrook, United States
  • Boeson Research · Provo, United States
across 2 updates, Sep 25, 2026 – Oct 19, 2026
Show all 2 updates
  1. Oct 19, 2026
    2 sites added
    Show 2 added (2 United States)
    • Flourish Research Andersonville · Northbrook, United States
    • Boeson Research · Provo, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    6 sites added
    Show 6 added (6 United States)
    • Progeny Psychiatric Clinic - Irvine · Irvine, United States
    • Accel Research - NeuroStudies · Decatur, United States
    • Josephson Wallack Munshower Neurology P.C. · Indianapolis, United States
    • ActivMed Practices & Research, LLC · Methuen, United States
    • Adams Clinical - Watertown · Watertown, United States
    • Mt. Olympus Medical Research, Llc - Katy · Katy, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07633470
Lead sponsor
Alpha Cognition, Inc
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
May 20, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Kurt P Grady, MBA
Contact
kgrady@alphacognition.com
(618) 407-6732

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion